You just read:

Eisai presentations at the Annual Meeting of the American Epilepsy Society (AES) included key data on long-term convulsive seizure-freedom rates of adjunctive perampanel (marketed as FYCOMPA® CIII) in adolescent patients, monotherapy in partial-onset seizures and healthcare utilization associated with perampanel therapy

News provided by

Eisai Inc.

Dec 06, 2017, 15:21 ET